MicroRNAs: Key Regulators in Lung Cancer.

Younes El Founini, Imane Chaoui, Hind Dehbi, Mohammed El Mzibri, Roger Abounader, Fadila Guessous
{"title":"MicroRNAs: Key Regulators in Lung Cancer.","authors":"Younes El Founini,&nbsp;Imane Chaoui,&nbsp;Hind Dehbi,&nbsp;Mohammed El Mzibri,&nbsp;Roger Abounader,&nbsp;Fadila Guessous","doi":"10.2174/2211536610666210527102522","DOIUrl":null,"url":null,"abstract":"<p><p>Noncoding RNAs have emerged as key regulators of the genome upon gene expression profiling and genome-wide sequencing. Among these noncoding RNAs, microRNAs are short noncoding RNAs that regulate a plethora of functions, biological processes and human diseases by targeting the messenger RNA stability through 3'UTR binding, leading to either mRNA cleavage or translation repression, depending on microRNA-mRNA complementarity degree. Additionally, strong evidence has suggested that dysregulation of miRNAs contributes to the etiology and progression of human cancers, such as lung cancer, the most common and deadliest cancer worldwide. Indeed, by acting as oncogenes or tumor suppressors, microRNAs control all aspects of lung cancer malignancy, including cell proliferation, survival, migration, invasion, angiogenesis, cancer stem cells, immune-surveillance escape, and therapy resistance; and their expressions are often associated with clinical parameters. Moreover, several deregulated microRNAs in lung cancer are carried by exosomes and microvesicles and secreted in body fluids, mainly the circulation, where they conserve their stable forms. Subsequently, seminal efforts have been focused on extracellular microRNAs levels as noninvasive diagnostic and prognostic biomarkers in lung cancer. In this review, focusing on recent literature, we summarize the deregulation, mechanisms of action, functions and highlight clinical applications of miRNAs for better management and design of future lung cancer targeted therapies.</p>","PeriodicalId":38067,"journal":{"name":"MicroRNA (Shariqah, United Arab Emirates)","volume":"10 2","pages":"109-122"},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"MicroRNA (Shariqah, United Arab Emirates)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/2211536610666210527102522","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 6

Abstract

Noncoding RNAs have emerged as key regulators of the genome upon gene expression profiling and genome-wide sequencing. Among these noncoding RNAs, microRNAs are short noncoding RNAs that regulate a plethora of functions, biological processes and human diseases by targeting the messenger RNA stability through 3'UTR binding, leading to either mRNA cleavage or translation repression, depending on microRNA-mRNA complementarity degree. Additionally, strong evidence has suggested that dysregulation of miRNAs contributes to the etiology and progression of human cancers, such as lung cancer, the most common and deadliest cancer worldwide. Indeed, by acting as oncogenes or tumor suppressors, microRNAs control all aspects of lung cancer malignancy, including cell proliferation, survival, migration, invasion, angiogenesis, cancer stem cells, immune-surveillance escape, and therapy resistance; and their expressions are often associated with clinical parameters. Moreover, several deregulated microRNAs in lung cancer are carried by exosomes and microvesicles and secreted in body fluids, mainly the circulation, where they conserve their stable forms. Subsequently, seminal efforts have been focused on extracellular microRNAs levels as noninvasive diagnostic and prognostic biomarkers in lung cancer. In this review, focusing on recent literature, we summarize the deregulation, mechanisms of action, functions and highlight clinical applications of miRNAs for better management and design of future lung cancer targeted therapies.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
microrna:肺癌的关键调控因子。
在基因表达谱和全基因组测序中,非编码rna已成为基因组的关键调控因子。在这些非编码RNA中,microrna是短的非编码RNA,通过3'UTR结合靶向信使RNA的稳定性,调节多种功能、生物过程和人类疾病,根据microRNA-mRNA的互补程度导致mRNA的切割或翻译抑制。此外,强有力的证据表明,mirna的失调有助于人类癌症的病因和进展,如肺癌,世界上最常见和最致命的癌症。事实上,通过作为癌基因或肿瘤抑制因子,microRNAs控制着肺癌恶性肿瘤的各个方面,包括细胞增殖、存活、迁移、侵袭、血管生成、癌症干细胞、免疫监视逃逸和治疗抵抗;它们的表达通常与临床参数有关。此外,肺癌中一些不受调控的小rna由外泌体和微囊携带,并在体液中分泌,主要是在循环中,它们保持其稳定的形式。随后,将细胞外microrna水平作为肺癌的无创诊断和预后生物标志物进行了开创性的研究。本文综述了近年来的文献,总结了mirna的调控、作用机制、功能,并重点介绍了mirna的临床应用,以更好地管理和设计未来的肺癌靶向治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
30
期刊最新文献
The Role of Noncoding RNAs in the Prognosis and Diagnosis of Colorectal Cancer: An Emerging Biomarker. Nanoparticle Carriers: A New Era of Precise CRISPR/Cas9 Gene Editing. Identification of Key miRNAs in Endometriosis. Key LncRNAs Associated with Distant Metastasis in Breast Cancer: A System Biology Analysis. Identification of miR-20a as a Diagnostic and Prognostic Biomarker in Colorectal Cancer: MicroRNA Sequencing and Machine Learning Analysis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1